Clinical Trial Update: Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating letrozole plus metronomic capecitabine as first-line therapy for recurrent or metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Letrozole (letrozole)

Snippet

Sponsor: Assiut University | Conditions: Metastasis Breast | Phase 2 | Status: UNKNOWN